Neurocrine Biosciences Reports Second Quarter 2022 Financial

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2022 and raised net...

Related Keywords

Japan , United States , Neurocrine Biosciences , Sosei Heptares , Neurocrine Bioscience , Kevin Gorman , Neurocrine Biosciences Inc , Sosei Group Corporation , Linkedin , Mitsubishi Tanabe Pharma Corporation , Takeda Pharmaceutical Company , Nasdaq , Prnewswire Neurocrine Biosciences Inc , Xenon Pharmaceuticals , Idorsia Pharmaceuticals , Second Quarter Net Product Sales , Product Sales Guidance Raised , Chief Executive Officer , Product Sales , Commercial Highlights , Operating Expense Guidance , Future Pipeline Milestones , Supplemental New Drug Application , Online Data , Line Registrational Data , Selectivet Type , Pediatric Epilepsy , Line Phase , Adrenal Hyperplasia , Major Depressive , Onset Seizure , Vesicular Monoamine Transporter , Calcium Channel , Epileptic Encephalopathy , Continuous Spike , Wave During Sleep , Corticotropin Releasing Factor Type , Isoxazole Propionic Acid , Orphang Protein Coupled Receptor , Sodium Channel , Bioscience Partners , East Asia , Takeda Pharmaceutical Company Limited , Webcast Today , Quarterly Report , Nc ,